Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer

For patients with EGFR PACC-mutated non-small compartment lung crab (NSCLC), the targeted therapy firmonertinib achieved durable antitumor enactment successful a Phase Ib proceedings led by researchers astatine The University of Texas MD Anderson Cancer Center, supporting an attack to selecting treatments based connected the structural features of uncommon EGFR mutations.